Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001
Erasca, Inc. (ERAS)
Company Research
Source: GlobeNewswire
The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043 Expands Erasca’s diversified IP portfolio for RAS-driven cancers Initial Phase 1 monotherapy data expected for ERAS-0015 in 1H and for ERAS-4001 in 2H 2026 SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Patent and Trademark Office has issued Patent No. 12,552,813, titled “Heterocyclic Substituted Pyrimidopyran Compound And Use Thereof.” The patent claims protect the composition of matter for Erasca’s potentially first-in-class pan-KRAS inhibitor ERAS-4001 and related compositions until June 2043, which may be subject to patent term adjustments or extensions affording even later protection. “This newly issued U.S. patent strengthens our E
Show less
Read more
Impact Snapshot
Event Time:
ERAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ERAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ERAS alerts
High impacting Erasca, Inc. news events
Weekly update
A roundup of the hottest topics
ERAS
News
- Tango rises after Q4 results, clinical pact with Erasca [Seeking Alpha]Seeking Alpha
- Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights [Yahoo! Finance]Yahoo! Finance
- Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat [Yahoo! Finance]Yahoo! Finance
- Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and VopimetostatGlobeNewswire
- Assessing Erasca (ERAS) Valuation After Strong Recent Share Price Momentum [Yahoo! Finance]Yahoo! Finance
ERAS
Earnings
- 11/12/25 - In-Line
ERAS
Sec Filings
- 3/6/26 - Form 4
- 3/4/26 - Form 144
- 2/17/26 - Form 144
- ERAS's page on the SEC website